Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business UpdateGlobeNewsWire • 08/10/20
UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisGlobeNewsWire • 06/30/20
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisGlobeNewsWire • 06/30/20
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business UpdateGlobeNewsWire • 05/11/20
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH CirrhosisGlobeNewsWire • 04/30/20
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH CirrhosisGlobeNewsWire • 12/05/19
Merck's Keytruda + Galectin's Belapectin (GR-MD-02): Thoughts On The EvidenceSeeking Alpha • 04/17/19